(HWKN) Hawkins - Ratings and Ratios
Chemicals, Ingredients, Water-Treatment, Industrial-Blends, Nutraceuticals
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.55% |
| Yield on Cost 5y | 2.95% |
| Yield CAGR 5y | 4.19% |
| Payout Consistency | 98.0% |
| Payout Ratio | 18.3% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 37.4% |
| Value at Risk 5%th | 55.5% |
| Relative Tail Risk | -9.89% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.87 |
| Alpha | 22.06 |
| CAGR/Max DD | 1.72 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.596 |
| Beta | 0.786 |
| Beta Downside | 0.402 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.79% |
| Mean DD | 7.56% |
| Median DD | 4.83% |
Description: HWKN Hawkins January 12, 2026
Hawkins, Inc. (NASDAQ:HWKN) is a U.S.–based provider of water-treatment chemicals, industrial specialty chemicals, and health-nutrition ingredients. The business is organized into three segments: (1) Water Treatment, which supplies chemicals, equipment, and services for potable, municipal, industrial, agricultural, and swimming-pool water; (2) Industrial, which manufactures and distributes bulk and blended chemicals-including sodium hypochlorite, liquid caustic soda, and phosphoric acid-for sectors such as agriculture, electronics, energy, and pharmaceuticals; and (3) Health & Nutrition, which distributes minerals, vitamins, amino acids, botanicals, and other functional ingredients to nutraceutical and personal-care manufacturers.
In FY 2023 Hawkins reported revenue of approximately $1.1 billion, a 5 % year-over-year increase driven primarily by higher demand for water-treatment solutions in municipalities coping with aging infrastructure. Adjusted EBITDA margin hovered around 12 %, reflecting modest pricing power but also exposure to raw-material cost volatility (e.g., chlorine and caustic soda). The global water-treatment market is projected to grow at a 5-6 % CAGR through 2029, while specialty chemicals for health-nutrition benefit from secular trends in functional foods and aging populations, both of which support demand growth for Hawkins’ ingredient portfolio.
If you want a data-rich, quantitative deep-dive on HWKN’s valuation and risk profile, the ValueRay platform offers a concise analyst dashboard that can help you benchmark the company against peers.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 83.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -3.82 > 1.0 |
| NWC/Revenue: 13.49% < 20% (prev 12.58%; Δ 0.91% < -1%) |
| CFO/TA 0.12 > 3% & CFO 122.9m > Net Income 83.1m |
| Net Debt (282.8m) to EBITDA (158.1m): 1.79 < 3 |
| Current Ratio: 2.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (20.8m) vs 12m ago -0.07% < -2% |
| Gross Margin: 23.03% > 18% (prev 0.23%; Δ 2280 % > 0.5%) |
| Asset Turnover: 124.9% > 50% (prev 135.5%; Δ -10.59% > 0%) |
| Interest Coverage Ratio: 12.43 > 6 (EBITDA TTM 158.1m / Interest Expense TTM 9.84m) |
Altman Z'' (< 1.1 .. > 2.6) 4.56
| A: 0.14 (Total Current Assets 239.6m - Total Current Liabilities 98.6m) / Total Assets 984.2m |
| B: 0.49 (Retained Earnings 478.3m / Total Assets 984.2m) |
| C: 0.15 (EBIT TTM 122.4m / Avg Total Assets 836.9m) |
| D: 1.01 (Book Value of Equity 479.7m / Total Liabilities 477.2m) |
| Altman-Z'' Score: 4.56 = AA |
ValueRay F-Score (Strict, 0-100) 69.92
| 1. Piotroski: 6.50pt |
| 2. FCF Yield: 2.28% |
| 3. FCF Margin: 7.54% |
| 4. Debt/Equity: 0.58 |
| 5. Debt/Ebitda: 1.79 |
| 6. ROIC - WACC: 4.91% |
| 7. RoE: 17.42% |
| 8. Revenue Trend: 63.84% |
| 9. EPS Trend: 5.39% |
What is the price of HWKN shares?
Over the past week, the price has changed by +1.62%, over one month by +4.32%, over three months by -5.74% and over the past year by +33.71%.
Is HWKN a buy, sell or hold?
- Strong Buy: 0
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HWKN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 188 | 22% |
| Analysts Target Price | 188 | 22% |
| ValueRay Target Price | 232.6 | 51% |
HWKN Fundamental Data Overview January 19, 2026
P/E Forward = 31.4465
P/S = 3.0379
P/B = 6.2633
P/EG = 2.2615
Revenue TTM = 1.05b USD
EBIT TTM = 122.4m USD
EBITDA TTM = 158.1m USD
Long Term Debt = 268.3m USD (from longTermDebt, last quarter)
Short Term Debt = 9.81m USD (from shortTermDebt, last quarter)
Debt = 293.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 282.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.46b USD (3.18b + Debt 293.3m - CCE 10.4m)
Interest Coverage Ratio = 12.43 (Ebit TTM 122.4m / Interest Expense TTM 9.84m)
EV/FCF = 43.91x (Enterprise Value 3.46b / FCF TTM 78.8m)
FCF Yield = 2.28% (FCF TTM 78.8m / Enterprise Value 3.46b)
FCF Margin = 7.54% (FCF TTM 78.8m / Revenue TTM 1.05b)
Net Margin = 7.95% (Net Income TTM 83.1m / Revenue TTM 1.05b)
Gross Margin = 23.03% ((Revenue TTM 1.05b - Cost of Revenue TTM 804.6m) / Revenue TTM)
Gross Margin QoQ = 24.12% (prev 24.67%)
Tobins Q-Ratio = 3.51 (Enterprise Value 3.46b / Total Assets 984.2m)
Interest Expense / Debt = 1.31% (Interest Expense 3.83m / Debt 293.3m)
Taxrate = 26.70% (8.23m / 30.8m)
NOPAT = 89.7m (EBIT 122.4m * (1 - 26.70%))
Current Ratio = 2.43 (Total Current Assets 239.6m / Total Current Liabilities 98.6m)
Debt / Equity = 0.58 (Debt 293.3m / totalStockholderEquity, last quarter 507.0m)
Debt / EBITDA = 1.79 (Net Debt 282.8m / EBITDA 158.1m)
Debt / FCF = 3.59 (Net Debt 282.8m / FCF TTM 78.8m)
Total Stockholder Equity = 477.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.93% (Net Income 83.1m / Total Assets 984.2m)
RoE = 17.42% (Net Income TTM 83.1m / Total Stockholder Equity 477.2m)
RoCE = 16.42% (EBIT 122.4m / Capital Employed (Equity 477.2m + L.T.Debt 268.3m))
RoIC = 13.06% (NOPAT 89.7m / Invested Capital 686.9m)
WACC = 8.15% (E(3.18b)/V(3.47b) * Re(8.81%) + D(293.3m)/V(3.47b) * Rd(1.31%) * (1-Tc(0.27)))
Discount Rate = 8.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.15%
[DCF Debug] Terminal Value 74.36% ; FCFF base≈79.9m ; Y1≈66.0m ; Y5≈47.6m
Fair Price DCF = 27.13 (EV 849.6m - Net Debt 282.8m = Equity 566.8m / Shares 20.9m; r=8.15% [WACC]; 5y FCF grow -20.97% → 2.90% )
EPS Correlation: 5.39 | EPS CAGR: -40.46% | SUE: -4.0 | # QB: 0
Revenue Correlation: 63.84 | Revenue CAGR: 11.40% | SUE: -0.34 | # QB: 0
EPS current Year (2026-03-31): EPS=3.98 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-2.1% | Growth Revenue=+11.9%
EPS next Year (2027-03-31): EPS=4.41 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+10.7% | Growth Revenue=+7.5%
Additional Sources for HWKN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle